UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53
UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.
Stocks · News reference
Nektar Therapeutics shares are trading lower after the company announced 52-week data from its Phase 2b REZOLVE-AA study in patients with severe-to-very-severe alopecia areata that may not sufficiently robust for investors. Also, investors may be trimming positions after a 15-month rally with Phase 3 results expected next year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating